Literature DB >> 16200209

Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice.

David G Motto1, Anil K Chauhan, Guojing Zhu, Jonathon Homeister, Colin B Lamb, Karl C Desch, Weirui Zhang, Han-Mou Tsai, Denisa D Wagner, David Ginsburg.   

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a life-threatening illness caused by deficiency of the vWF-cleaving protease ADAMTS13. Here we show that ADAMTS13-deficient mice are viable and exhibit normal survival, although vWF-mediated platelet-endothelial interactions are significantly prolonged. Introduction of the genetic background CASA/Rk (a mouse strain with elevated plasma vWF) resulted in the appearance of spontaneous thrombocytopenia in a subset of ADAMTS13-deficient mice and significantly decreased survival. Challenge of these mice with shigatoxin (derived from bacterial pathogens associated with the related human disease hemolytic uremic syndrome) resulted in a striking syndrome closely resembling human TTP. Surprisingly, no correlation was observed between plasma vWF level and severity of TTP, implying the existence of TTP-modifying genes distinct from vWF. These data suggest that microbe-derived toxins (or possibly other sources of endothelial injury), together with additional genetic susceptibility factors, are required to trigger TTP in the setting of ADAMTS13 deficiency.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16200209      PMCID: PMC1240119          DOI: 10.1172/JCI26007

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Inducible secretion of large, biologically potent von Willebrand factor multimers.

Authors:  L A Sporn; V J Marder; D D Wagner
Journal:  Cell       Date:  1986-07-18       Impact factor: 41.582

2.  Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen.

Authors:  Y Asada; A Sumiyoshi; T Hayashi; J Suzumiya; K Kaketani
Journal:  Thromb Res       Date:  1985-06-01       Impact factor: 3.944

3.  Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.

Authors:  J L Moake; C K Rudy; J H Troll; M J Weinstein; N M Colannino; J Azocar; R H Seder; S L Hong; D Deykin
Journal:  N Engl J Med       Date:  1982-12-02       Impact factor: 91.245

4.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

Authors:  G A Rock; K H Shumak; N A Buskard; V S Blanchette; J G Kelton; R C Nair; R A Spasoff
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

5.  Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor.

Authors:  J A Dent; S D Berkowitz; J Ware; C K Kasper; Z M Ruggeri
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

6.  VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13.

Authors:  Koichi Kokame; Masanori Matsumoto; Yoshihiro Fujimura; Toshiyuki Miyata
Journal:  Blood       Date:  2003-09-25       Impact factor: 22.113

7.  The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

Authors:  Masanori Matsumoto; Hideo Yagi; Hiromichi Ishizashi; Hideo Wada; Yoshihiro Fujimura
Journal:  Semin Hematol       Date:  2004-01       Impact factor: 3.851

8.  Identification of strain-specific variants of mouse Adamts13 gene encoding von Willebrand factor-cleaving protease.

Authors:  Fumiaki Banno; Kazuyoshi Kaminaka; Kenji Soejima; Koichi Kokame; Toshiyuki Miyata
Journal:  J Biol Chem       Date:  2004-05-10       Impact factor: 5.157

9.  Genetic dissection of complex traits with chromosome substitution strains of mice.

Authors:  Jonathan B Singer; Annie E Hill; Lindsay C Burrage; Keith R Olszens; Junghan Song; Monica Justice; William E O'Brien; David V Conti; John S Witte; Eric S Lander; Joseph H Nadeau
Journal:  Science       Date:  2004-03-18       Impact factor: 47.728

10.  Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins.

Authors:  Jan-Dirk Studt; Johanna A Kremer Hovinga; Radovan Radonic; Vladimir Gasparovic; Dragutin Ivanovic; Marijan Merkler; Urs Wirthmueller; Clemens Dahinden; Miha Furlan; Bernhard Lämmle
Journal:  Blood       Date:  2004-02-24       Impact factor: 22.113

View more
  108 in total

Review 1.  Extracellular matrix proteins in hemostasis and thrombosis.

Authors:  Wolfgang Bergmeier; Richard O Hynes
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-02-01       Impact factor: 10.005

2.  Correction of a murine model of von Willebrand disease by gene transfer.

Authors:  Robert G Pergolizzi; Guangchun Jin; Diane Chan; Lorraine Pierre; James Bussel; Barbara Ferris; Philip L Leopold; Ronald G Crystal
Journal:  Blood       Date:  2006-04-25       Impact factor: 22.113

3.  In vitro microvessels for the study of angiogenesis and thrombosis.

Authors:  Ying Zheng; Junmei Chen; Michael Craven; Nak Won Choi; Samuel Totorica; Anthony Diaz-Santana; Pouneh Kermani; Barbara Hempstead; Claudia Fischbach-Teschl; José A López; Abraham D Stroock
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-29       Impact factor: 11.205

4.  Shiga toxin B subunits induce VWF secretion by human endothelial cells and thrombotic microangiopathy in ADAMTS13-deficient mice.

Authors:  Jing Huang; David G Motto; David R Bundle; J Evan Sadler
Journal:  Blood       Date:  2010-07-19       Impact factor: 22.113

5.  Atypical presentations of thrombotic thrombocytopenic purpura: a diagnostic role for ADAMTS13.

Authors:  Yosef Kalish; Amihai Rottenstreich; Deborah Rund; Sarit Hochberg-Klein
Journal:  J Thromb Thrombolysis       Date:  2016-08       Impact factor: 2.300

Review 6.  Microvascular platforms for the study of platelet-vessel wall interactions.

Authors:  Ying Zheng; Junmei Chen; José A López
Journal:  Thromb Res       Date:  2014-01-07       Impact factor: 3.944

Review 7.  ADAMTS13: more than a regulator of thrombosis.

Authors:  Yun Feng; Xueyin Li; Juan Xiao; Wei Li; Jing Liu; Xue Zeng; Xi Chen; Suhua Chen
Journal:  Int J Hematol       Date:  2016-10-01       Impact factor: 2.490

8.  Correction of ADAMTS13 deficiency by in utero gene transfer of lentiviral vector encoding ADAMTS13 genes.

Authors:  Masami Niiya; Masayuki Endo; Dezhi Shang; Philip W Zoltick; Nidal E Muvarak; Wenjing Cao; Sheng-Yu Jin; Christopher G Skipwith; David G Motto; Alan W Flake; X Long Zheng
Journal:  Mol Ther       Date:  2008-10-28       Impact factor: 11.454

9.  Role of reduced ADAMTS13 in arterial ischemic stroke: a pediatric cohort study.

Authors:  Moritz Lambers; Neil A Goldenberg; Gili Kenet; Fenella J Kirkham; Daniela Manner; Timothy Bernard; Rolf M Mesters; Ralf Junker; Monika Stoll; Ulrike Nowak-Göttl
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

10.  Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy.

Authors:  Pablo Laje; Dezhi Shang; Wenjing Cao; Masami Niiya; Masayuki Endo; Antoneta Radu; Nicole DeRogatis; Friedrich Scheiflinger; Philip W Zoltick; Alan W Flake; X Long Zheng
Journal:  Blood       Date:  2009-01-13       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.